Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination With Vandetanib.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2014
At a glance
- Drugs Paclitaxel (Primary) ; Vandetanib (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 27 Feb 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 14 Feb 2012 Actual patient number (65) and Celgene Corporation as trial company added as reported by ClinicalTrials.gov.